The philosophy behind value investing is as relevant today as it was when Benjamin Graham first laid out its principles nearly a century ago. The core idea—buying companies whose market price sits below an estimate of their intrinsic worth—requires patience, discipline, and a systematic approach to filtering the market. One practical way to surface candidates that fit this profile is to look for stocks that are attractively valued relative to their peers, while still maintaining solid business fundamentals. A screen designed for "decent value" scans for exactly that combination: a strong valuation score, coupled with respectable readings on profitability, financial health, and growth. The following security emerged from that specific process and presents a strong case for further investigation.
Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) is a biopharmaceutical company focused on developing and commercializing novel therapeutics based on ribonucleic acid interference (RNAi). With a portfolio of marketed products including ONPATTRO, AMVUTTRA, GIVLAARI, and OXLUMO, the company has transitioned from a pure-play research stage into a commercial entity with a growing revenue base and a deep pipeline of clinical candidates. The company’s fundamental profile, as derived from its recent financial data, offers an interesting blend of attributes that are particularly relevant for value-focused investors.
Valuation: Priced Below Its Industry Peers
The most critical pillar of any value thesis is valuation, and here Alnylam scores a solid 7 out of 10. On an absolute basis, the stock may not look cheap: its trailing Price/Earnings ratio stands at 72.05, and its Price/Forward Earnings sits at 25.69. However, context is everything. Within the biotechnology industry, where many companies trade at high multiples on minimal or negative earnings, Alnylam is actually priced at a discount compared to a significant portion of its peer group. The company is cheaper than over 90% of its industry peers based on both the trailing P/E and the forward P/E ratios. Furthermore, when looking at Enterprise Value to EBITDA and Price to Free Cash Flow, Alnylam again ranks among the most attractively valued stocks in its sector.
What makes this valuation profile particularly strong for a value investor is the "compensation for growth." The company’s low PEG ratio—which adjusts the P/E for the expected earnings growth rate—indicates that the current multiple is not excessive given the projected trajectory. With earnings expected to grow by over 92% in the coming year, the market appears to be pricing in a future that may already be reflected in analyst estimates, but not yet fully realized in the current share price relative to the industry.
Growth: A Strong Outperformance
A value stock that is also growing rapidly is a rare find. Alnylam scores a 8 out of 10 on growth, bolstered by exceptional recent performance. Revenue expanded by 82.57% in the last year alone, building on a five-year average growth rate of nearly 50% per year. Earnings per share have been even more explosive, growing by 288.04% over the past twelve months. Looking ahead, analysts expect EPS to continue compounding at an average of 61.72% per year, with revenue growth projected at 25.54% annually.
This kind of growth is important for value investors because it reduces the risk of a "value trap." A company that is growing its top and bottom lines at such a pace is more likely to close the gap between its current market price and its intrinsic value. Strong growth helps ensure that the undervaluation is a temporary market mispricing rather than a permanent reflection of a dying business.
Profitability: Margin Strength and Returns
The profitability rating of 6 out of 10 reinforces the quality of the business. While the score is decent, the underlying details reveal a company with impressive margins and returns. Gross margin sits at 80.83%, operating margin at 17.54%, and net profit margin at 13.46%—all of which rank among the top 85% to 93% of industry peers. Returns on capital are equally strong: Return on Assets (11.25%), Return on Equity (53.68%), and Return on Invested Capital (15.72%) each outperform over 93% of comparable companies.
These metrics matter because they indicate that Alnylam is not just growing revenue, but is doing so profitably and efficiently. High returns on capital are a hallmark of a business with a competitive advantage, which is precisely the kind of moat value investors look for to protect their downside.
Financial Health: Stability with a Caveat
The financial health rating of 5 out of 10 is the most moderate score in the profile, and it deserves scrutiny. On the positive side, the Altman-Z score of 5.81 signals a very low risk of bankruptcy, and the current ratio of 3.13 (along with a quick ratio of 3.06) indicates strong liquidity. The company has also been reducing its debt-to-assets ratio year-over-year, which is a favorable trend.
However, the Debt to Equity ratio of 2.31 is high, placing Alnylam in the bottom 20% of its industry for this metric. This reliance on external financing is a risk that value investors should monitor, especially in a rising interest rate environment. Yet, the debt to free cash flow ratio of 4.22 is manageable and actually ranks among the best in the industry, suggesting that the company’s cash generation is sufficient to service its obligations over a reasonable timeframe.
For a full breakdown of how these five fundamental pillars—valuation, growth, profitability, health, and dividend—score against industry peers, the detailed fundamental analysis report provides all the underlying data and comparisons.
Bottom Line for the Value Investor
Alnylam Pharmaceuticals presents an interesting case for the value investor who is willing to look beyond headline multiples. It offers a rare combination of strong growth, industry-leading profitability margins, and a valuation that is cheap compared to the majority of its biotech peers. While its debt load and average health score are risk factors that cannot be ignored, the company’s liquidity, cash flow, and rapid earnings expansion provide a buffer. This stock fits the "decent value" profile because it delivers on the valuation front without sacrificing the other pillars that support a sustainable business.
If you are looking for more opportunities that combine strong valuation with decent profitability, health, and growth, you can explore a full list of similar stocks by using this value-focused stock screener to find additional candidates that match these criteria.
Disclaimer: This article is for informational and educational purposes only and does not constitute investment advice. Always conduct your own research and consider your financial situation before making investment decisions.
Read full article here »
View the Zacks #1 Rank List
Alnylam Pharmaceuticals (NASDAQ:ALNY): A Value Stock Priced Below Biotech Peers with Strong Growth
The philosophy behind value investing is as relevant today as it was when Benjamin Graham first laid out its principles nearly a century ago. The core idea—buying companies whose market price sits below an estimate of their intrinsic worth—requires patience, discipline, and a systematic approach to filtering the market. One practical way to surface candidates that fit this profile is to look for stocks that are attractively valued relative to their peers, while still maintaining solid business fundamentals. A screen designed for "decent value" scans for exactly that combination: a strong valuation score, coupled with respectable readings on profitability, financial health, and growth. The following security emerged from that specific process and presents a strong case for further investigation.
Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) is a biopharmaceutical company focused on developing and commercializing novel therapeutics based on ribonucleic acid interference (RNAi). With a portfolio of marketed products including ONPATTRO, AMVUTTRA, GIVLAARI, and OXLUMO, the company has transitioned from a pure-play research stage into a commercial entity with a growing revenue base and a deep pipeline of clinical candidates. The company’s fundamental profile, as derived from its recent financial data, offers an interesting blend of attributes that are particularly relevant for value-focused investors.
Valuation: Priced Below Its Industry Peers
The most critical pillar of any value thesis is valuation, and here Alnylam scores a solid 7 out of 10. On an absolute basis, the stock may not look cheap: its trailing Price/Earnings ratio stands at 72.05, and its Price/Forward Earnings sits at 25.69. However, context is everything. Within the biotechnology industry, where many companies trade at high multiples on minimal or negative earnings, Alnylam is actually priced at a discount compared to a significant portion of its peer group. The company is cheaper than over 90% of its industry peers based on both the trailing P/E and the forward P/E ratios. Furthermore, when looking at Enterprise Value to EBITDA and Price to Free Cash Flow, Alnylam again ranks among the most attractively valued stocks in its sector.
What makes this valuation profile particularly strong for a value investor is the "compensation for growth." The company’s low PEG ratio—which adjusts the P/E for the expected earnings growth rate—indicates that the current multiple is not excessive given the projected trajectory. With earnings expected to grow by over 92% in the coming year, the market appears to be pricing in a future that may already be reflected in analyst estimates, but not yet fully realized in the current share price relative to the industry.
Growth: A Strong Outperformance
A value stock that is also growing rapidly is a rare find. Alnylam scores a 8 out of 10 on growth, bolstered by exceptional recent performance. Revenue expanded by 82.57% in the last year alone, building on a five-year average growth rate of nearly 50% per year. Earnings per share have been even more explosive, growing by 288.04% over the past twelve months. Looking ahead, analysts expect EPS to continue compounding at an average of 61.72% per year, with revenue growth projected at 25.54% annually.
This kind of growth is important for value investors because it reduces the risk of a "value trap." A company that is growing its top and bottom lines at such a pace is more likely to close the gap between its current market price and its intrinsic value. Strong growth helps ensure that the undervaluation is a temporary market mispricing rather than a permanent reflection of a dying business.
Profitability: Margin Strength and Returns
The profitability rating of 6 out of 10 reinforces the quality of the business. While the score is decent, the underlying details reveal a company with impressive margins and returns. Gross margin sits at 80.83%, operating margin at 17.54%, and net profit margin at 13.46%—all of which rank among the top 85% to 93% of industry peers. Returns on capital are equally strong: Return on Assets (11.25%), Return on Equity (53.68%), and Return on Invested Capital (15.72%) each outperform over 93% of comparable companies.
These metrics matter because they indicate that Alnylam is not just growing revenue, but is doing so profitably and efficiently. High returns on capital are a hallmark of a business with a competitive advantage, which is precisely the kind of moat value investors look for to protect their downside.
Financial Health: Stability with a Caveat
The financial health rating of 5 out of 10 is the most moderate score in the profile, and it deserves scrutiny. On the positive side, the Altman-Z score of 5.81 signals a very low risk of bankruptcy, and the current ratio of 3.13 (along with a quick ratio of 3.06) indicates strong liquidity. The company has also been reducing its debt-to-assets ratio year-over-year, which is a favorable trend.
However, the Debt to Equity ratio of 2.31 is high, placing Alnylam in the bottom 20% of its industry for this metric. This reliance on external financing is a risk that value investors should monitor, especially in a rising interest rate environment. Yet, the debt to free cash flow ratio of 4.22 is manageable and actually ranks among the best in the industry, suggesting that the company’s cash generation is sufficient to service its obligations over a reasonable timeframe.
For a full breakdown of how these five fundamental pillars—valuation, growth, profitability, health, and dividend—score against industry peers, the detailed fundamental analysis report provides all the underlying data and comparisons.
Bottom Line for the Value Investor
Alnylam Pharmaceuticals presents an interesting case for the value investor who is willing to look beyond headline multiples. It offers a rare combination of strong growth, industry-leading profitability margins, and a valuation that is cheap compared to the majority of its biotech peers. While its debt load and average health score are risk factors that cannot be ignored, the company’s liquidity, cash flow, and rapid earnings expansion provide a buffer. This stock fits the "decent value" profile because it delivers on the valuation front without sacrificing the other pillars that support a sustainable business.
If you are looking for more opportunities that combine strong valuation with decent profitability, health, and growth, you can explore a full list of similar stocks by using this value-focused stock screener to find additional candidates that match these criteria.
Disclaimer: This article is for informational and educational purposes only and does not constitute investment advice. Always conduct your own research and consider your financial situation before making investment decisions.
Read full article here »